The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...
UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback